In vitro evaluation of microfluidic WS6-loaded Eudragit nanoparticles for improving insulin-producing cell differentiation
PLOS One · 04.08.2026 · 21 (8) · e0354587
DOI: 10.1371/journal.pone.0354587 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 04.08.2026. Verfasst von Duaa Abuarqoub und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan. Hauptthemen laut MEDLINE: Cell Differentiation, Nanoparticles, Insulin-Secreting Cells, Acrylic Resins. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the scientific research funding provided by the Ministry of Higher Educatio, Deanship of Scientific Research, University of Petra.
Abstract (Originalsprache)
This study explores a stem-cell–based approach for diabetes treatment by enhancing the viability and functionality of insulin-producing cells (IPCs) derived from stem cells of the apical papilla (SCAP). Although SCAP can differentiate into IPCs, limited cell survival remains a challenge. To address this, the proliferation enhancer WS6 was incorporated into Eudragit RS100 nanoparticles (NPs) using microfluidics. The WS6-loaded NPs were characterized for size, charge, PDI, morphology, stability, and drug loading. An MTT assay was performed as a preliminary screening method to evaluate the cytocompatibility of blank-NPs and to optimize treatment concentration. SCAP cells were treated with free WS6 or WS6-loaded NPs, and cellular uptake of NPs was evaluated using flow cytometry and fluorescence imaging. Additionally, the viability of treated cells was determined by propidium iodide (PI) and trypan blue. Prior to differentiation, definitive endoderm formation was assessed through SOX17 and FOXA2 expressions. After differentiation into IPCs, maturation markers such as insulin, C-peptide, PDX-1, NKX2.2, and NKX6.1 were examined, and apoptosis assays measured cell viability. Functional insulin secretion was tested using an in vitro glucose-stimulated insulin secretion (GSIS) assay. Results showed that WS6-loaded NPs significantly improved SCAP viability, increased healthy cell percentages, and enhanced IPC maturation. Treated IPCs demonstrated functional insulin secretion and improved glucose regulation. Overall, WS6-loaded NPs represent a promising approach to enhance IPC proliferation and generation for diabetes therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan.
- Department of Applied Medical Sciences, Al Hussein Bin Abdullah II Academy for Civil Protection, Al-Balqa Applied University, Salt, Jordan.
- Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman, Jordan.
ORCID-Profile: Duaa Abuarqoub, Mohammad Abuoun
Förderung
- the scientific research funding provided by the Ministry of Higher Educatio
- Deanship of Scientific Research, University of Petra
Zitieren
APA
Abuarqoub, D., Mohammad, M., Albarghouthi, R., Abuoun, M., Alnatour, M., Alhawarat, F., & Jaradat, A. (2026). In vitro evaluation of microfluidic WS6-loaded Eudragit nanoparticles for improving insulin-producing cell differentiation. PLOS One, 21(8), e0354587. https://doi.org/10.1371/journal.pone.0354587
Vancouver
Abuarqoub D, Mohammad M, Albarghouthi R, Abuoun M, Alnatour M, Alhawarat F, et al. In vitro evaluation of microfluidic WS6-loaded Eudragit nanoparticles for improving insulin-producing cell differentiation. PLOS One. 2026;21(8):e0354587. doi:10.1371/journal.pone.0354587
BibTeX
@article{Abuarqoub2026,
author = {Abuarqoub, Duaa and Mohammad, Marwa and Albarghouthi, Rand and Abuoun, Mohammad and Alnatour, Mohammad and Alhawarat, Fuad and Jaradat, Abdolelah},
title = {In vitro evaluation of microfluidic WS6-loaded Eudragit nanoparticles for improving insulin-producing cell differentiation},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {8},
pages = {e0354587},
doi = {10.1371/journal.pone.0354587}
}
EUVIMED